MedTrace Logo

Assessment Of Safety Of UK-390,957

NCT00219609 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1058

Last updated 2012-11-07

No results posted yet for this study

Summary

To determine whether UK-390,957 is a safe treatment for premature ejaculation.

Conditions

  • Ejaculation

Interventions

DRUG

UK-390,957

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • Czechia
  • France
  • Germany
  • Israel
  • Italy
  • Norway
  • Poland
  • Sweden
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219609 on ClinicalTrials.gov